Aeonose™ for COVID-19
SARS-CoV-2 Infection Detection
Clinical ValidationActive
Key Facts
Indication
SARS-CoV-2 Infection Detection
Phase
Clinical Validation
Status
Active
Company
About The eNose Company
The eNose Company's mission is to transform diagnostics through its portable, non-invasive Aeonose™ technology, which analyzes breath to detect diseases like lung cancer and tuberculosis within minutes. Key achievements include CE-marking for its device, multiple published clinical studies, and a public listing to fund commercialization. Its strategy is to validate its platform across multiple high-burden indications, securing regulatory approvals and building partnerships for global deployment in screening and triage settings.
View full company profile